For most biopharma companies, the top three considerations when choosing a contract development and manufacturing organization (CDMO) for outsourcing drug development activities are scientific expertise, equipment/capacity, and how well the organization manages partnerships and expectations. However, a fourth parameter has assumed significance in recent times. A partner ecosystem that is self-sufficient and can sustain even during a pandemic, i.e., End-to-end development capabilities all in one campus!
Syngene is among the few CDMOs equipped with co-localized capabilities across the drug discovery, development, and manufacturing continuum, all in one campus. This has resulted in significant cost-efficiencies, besides accelerating drug development timelines for our clients. The reasons are not far to seek. Co-location has helped Syngene manage projects centrally, unhindered by logistical/shipping delays or dependencies on third-party deliverables.
Currently, we are the preferred partner to 400+ global organizations with 400+ patents where we have been recognized as co-innovators by our clients. We have the capability and experience to build a customized journey path to take your molecule from early discovery all the way to commercial manufacturing in the shortest possible time.
You can now take a 360-degree virtual tour of our facilities that enable the Drug Development journey across Chemical, Formulation, Clinical and Manufacturing. Start your tour now!
Syngene International Limited. All rights reserved © 2023